Exploratory investigation of discovering novel biomarker to predict efficacy of chemotherapy ncluding bevacizumab in patients with advanced ovarian cancer

Exploratory investigation of discovering novel biomarker to predict efficacy of chemotherapy ncluding bevacizumab in patients with advanced ovarian cancer - Predictive therapeutic marker of bevacizumab against patients with ovarian cancer

Status

Active, not recruiting

Phases

Unknown

Study type

Interventional

Source

JPRN

Registry ID

JPRN-UMIN000022481

Enrollment

Registered

2016-05-27

Start date

2016-05-25

Completion date

Unknown

Last updated

2026-06-29

For informational purposes only — not medical advice. Sourced from public registries and may not reflect the latest updates. Terms

Conditions

Advanced ovarian cancer

Interventions

All patients undergo FDG-PET/MRI before and 4 weeks after initiation of bevacizumab therapy.

Eligibility

Sex/Gender

All

Inclusion criteria

Inclusion criteria: 1) Pathologically confirmed advanced ovarian cancer with stage III/IV 2) Eastern Cooperative Oncology Group (ECOG) performance status of 0 to 2 3) Patient with evaluable lesion based on RECIST 4) Written informed consent

Exclusion criteria

Exclusion criteria: 1) Pregnant woman 2) Patients with double primary cancer or serious infectious disease requring antibiotic therapy 3) Other cases attending physician it is determined unsuitable for registration of the study

Design outcomes

Primary

Measure	Time frame
Changeing of SUVmax, MTV and TLG, and the efficacy of bevacizumab Evaluation after 1 month from administration of bevacizumab Exploratory investigation of many biomarkers using blood sample	—

Countries

Japan

Contacts

Public ContactKyoichi Kaira

Gunma Univetsity Department of Oncology Clinical Development

kkaira1970@yahoo.co.jp027-220-8222

Outcome results

None listed

Source: JPRN (via WHO ICTRP) · Data processed: Jul 3, 2026